Patent ID: 6399628
Filing Date: 2002-06-04
Classification: A61K,C07C

Abstract:
A pharmaceutical composition comprising a pharmaceutically inert carrier and a pharmaceutically effective amount of a compound of formula I: whereinR1 is selected from the group consisting of: (a) a substituted phenyl group of formula II: â€ƒwherein Rc is selected from the group consisting of acyl, alkyl, alkoxy, alkoxycarbonyl, alkylalkoxy, azido, cyano, halo, hydrogen, nitro, trihalomethyl, thioalkoxy, and where Rb and Rc are fused to form a heteroaryl or heterocyclic ring with the phenyl ring wherein the heteroaryl or heterocyclic ring contains from 3 to 8 atoms of which from 1 to 3 are heteroatoms independently selected from the group consisting of oxygen, nitrogen and sulfur; Rb and Rbâ€² are independently selected from the group consisting of hydrogen, halo, nitro, cyano, trihalomethyl, alkoxy, and thioalkoxy with the proviso that Rb, Rbâ€² and Rc are not all hydrogen and with the further proviso that when Rc is hydrogen, then neither Rb nor Rbâ€² are hydrogen; (b) 2-naphthyl; and (c) 2-naphthyl substituted at the 4, 5, 6, 7 and/or 8 positions with 1 to 5 substituents selected from the group consisting of alkyl, alkoxy, halo, cyano, nitro, trihalomethyl, and thioalkoxy; R2 is selected from the group consisting of hydrogen, alkyl of from 1 to 4 carbon atoms, alkylalkoxy of from 1 to 4 carbon atoms and alkylthioalkoxy of from 1 to 4 carbon atoms; and R3 is selected from the group consisting of: (a) â€”Y(CH2)nCHR4R5 wherein n is an integer of from 0 to 2, Y is selected from the group consisting of oxygen and sulfur, R4 and R5 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, aryl optionally substituted with from 1 to 3 substituents selected from the group consisting of alkyl, alkoxy, halo, cyano, nitro, trihalomethyl, and thioalkoxy, heteroaryl optionally substituted with from 1 to 3 substituents selected from the group consisting of alkyl, alkoxy, halo, cyano, nitro, trihalomethyl, and thioalkoxy, and where R4 and R5 are joined to form a cycloalkyl group, a cycloalkenyl group or a heterocyclic group; (b) â€”ON&boxH;C(NH2)R6 where R6 is selected from the group consisting of alkyl, aryl, cycloalkyl, and heteroaryl; (c) â€”O(CH2)pC(O)OR7 wherein p is an integer of from 1 to 2 and R7 is alkyl; and (d) â€”NR8R9 wherein R8 and R9 are joined to form a pyrrolyl group; and pharmaceutically acceptable salts thereofwith the provisos that1. when R1 is the substituted phenyl group of formula II above, Rbâ€² is hydrogen, Rb and Rc are chloro, and R2 is methyl, then R3 is not â€”OCH(CH3)â€”&phgr;; 2. when R1 is the substituted phenyl group of formula II above, when Rbâ€² is hydrogen, Rb and Rc are chloro, and R3 is â€”OCH2CH3 then R2 is not hydrogen; 3. when R1 is the substituted phenyl group of formula II above, Rbâ€² is hydrogen, Rb and Rc are chloro, and R3 is â€”OCH2CH(CH3)2 then R2 is not â€”CH(CH3)CH2CH3; and 4. when R1 is N-methylindol-5-yl and R2 is methyl, then R3 is not â€”OCH2CH3.